Lilly Gastroenterology

✅ A big thank you to the clinicians, researchers, and teams who made ECCO 2026 so meaningful. We’re grateful to everyone who shared insights, questions, and experiences. We look forward to staying connected as we advance IBD care.

What is early disease clearance in IBD linked to? For HCPs, CMAT-11249. February 2026.

Can histologic remission be the ultimate management goal in UC? Prof. Peter Irving discusses why histologic remission may predict outcomes beyond mucosal healing and why dedicated histology assessment matters. Follow for more.

In Crohn’s disease, imaging-assessed transmural healing has been associated with fewer admissions, surgery, and disease escalation. Could imaging-based targets inform long term management? Follow us for more insights.

In UC, which histologic endpoint best predicts relapse risk? For HCPs, CMAT-11249. February 2026.

Should management in Crohn’s disease extend beyond symptoms to include histologic assessment? Achieving histologic remission is associated with fewer relapses over 1–3 years versus persistent histologic activity.¹ Share your thoughts and follow us for more.

Over 44% of patients with UC experience sub-optimal disease control, characterised by steroid overuse and complications such as surgery and hospitalisation.¹ Could targeting endoscopic healing help improve long-term outcomes in patients with UC? Follow us to know more.

fCLP trends can signal UC/CD flares months before symptoms. Could monitoring fCLP levels enable earlier, targeted intervention? Follow us for more insights.

Which statement about faecal calprotectin in IBD is correct? For HCPs, CMAT-11249. February 2026.

Corticosteroid exposure appears to be associated with more adverse events over 1 year. How could this evidence inform practice? Follow us for more.

How do PROs complement objective measures in Crohn’s disease management? Prof. Mette Julsgaard discusses stool urgency and QoL alongside remission and endoscopic healing, and how combining them may provide a fuller view of activity. Watch the video. Follow us for more.

IBD affects more than the gut: emotional health and relationships can suffer. How can we better align management decisions with the challenges patients face beyond the symptoms? Follow us to know more.

Seeing the unseen in IBD: anxiety can intensify daily life. In early IBD, 37.2% report anxiety, with higher odds in CD than UC. Could recognising this symptom help reduce the psychological burden in patients? Follow us for more.

Why does bowel urgency occur in IBD? Dr. Alissa Walsh explains how neutrophil infiltration may damage the mucosa and sustain inflammation - driving urgency. Watch the video. Follow us for more.

Bowel urgency is one of UC’s most distressing symptoms;¹ are we using standardised, patient-centred questions to capture its daily impact? Save these steps – follow us for more.

Bowel urgency affects daily life in IBD. In a patient survey, 70.8% reported BU and 52.5% reported accidents. How do we close this communication gap? Join the discussion and follow for more.

What does holistic IBD management look like in practice? Prof. Peter Irving discusses how multidisciplinary teams improve continuity of support and outcomes across domains: from symptoms to histology to QoL. Watch the video. Follow us to stay updated.

In UC, which symptom is not among the top 5 most triggering for European patients? For HCPs, CMAT-11249. February 2026.

How is symptom relief related to inflammation control and mucosal healing in IBD? Follow us for more.

What are the benefits of gaining and maintaining remission in patients with IBD, and how can it help support patients through emotional and social challenges? Follow us for more insights.